Esperion Therapeutics is dedicated to the research, development, and commercialization of innovative therapies for managing elevated levels of low-density lipoprotein cholesterol (LDL-C). The company's primary focus is on addressing unmet needs in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). Their lead products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), represent significant advancements in oral, once-daily medicines for lowering LDL-C. Esperion's R&D efforts are geared towards expanding the therapeutic potential of bempedoic acid and exploring novel approaches to lipid management, with the goal of improving cardiovascular outcomes and reducing the burden of ASCVD.